New Study Confirms What Patients Have Been Saying: Bevacizumab Offers a Better Quality of Life

For people living with recurrent respiratory papillomatosis, the cycle of repeated surgeries is all too familiar. The constant appointments, the recoveries, the impact on your voice, your work, your daily routine. Many in our community have experienced dozens of procedures over the years. Some have had more than a hundred.

Now, a newly published study in Laryngoscope Investigative Otolaryngology offers something powerful: real data from real patients comparing their experiences with surgery and systemic bevacizumab treatment. The results confirm what many in our community have been saying for years. Bevacizumab can make a meaningful difference in quality of life.

What This Study Looked At

Researchers at Johns Hopkins University and Emory University surveyed 24 patients who had undergone both surgical treatment and systemic bevacizumab infusions for RRP. This is important because it allowed patients to directly compare their own experiences with each approach.

The study examined four key areas: quality of life, adverse effects, economic impact, and mental health. Participants answered questions about voice quality, breathing, swallowing, pain levels, recovery time, missed work, treatment-related fears, and overall outlook on the future.

The patients in this study had been living with RRP for an average of 31 years. They had undergone an average of 91 surgeries and 25 bevacizumab infusions. These are people who know what both treatment paths feel like.

The Results Were Clear

Across nearly all measures, patients reported better outcomes with bevacizumab than with surgery.

Voice, breathing, and swallowing all improved. Patients rated their voice quality, vocal range, breathing, and swallowing significantly higher during bevacizumab treatment. Half of patients reported "very good" voice quality with bevacizumab, compared to just 4% with surgery. Nearly 60% described their breathing as "very good" with bevacizumab, compared to 25% with surgery.

Vocal improvement lasted longer. On average, patients reported that the benefits of bevacizumab lasted about three months, compared to two months after surgery. Almost half of patients said their vocal improvement with bevacizumab persisted until their next infusion or remained stable over time.

Pain and recovery were dramatically different. The difference in pain levels was striking. Patients reported a median pain score of zero with bevacizumab infusions, compared to six out of ten following surgery. Every single patient in the study reported needing zero days of vocal rest after bevacizumab. In contrast, more than 60% needed one to three days of rest after surgery, and some needed a week or more.

Side effects were milder. Patients reported fewer and less severe side effects with bevacizumab. The most common issues were headaches, mild fatigue, and temporary blood pressure elevation. Surgery, on the other hand, was associated with long-term vocal cord scarring, anesthesia-related complications, and post-operative breathing and swallowing difficulties.

Fewer missed workdays. While treatment costs and travel time were similar between the two approaches, patients missed significantly fewer days of work with bevacizumab. More than 90% of patients missed zero to one workdays following an infusion, while surgery often meant two to five days away from work or more.

The Mental Health Impact

One of the most compelling parts of this study is how it captured the emotional toll of repeated surgeries and the relief that bevacizumab can provide.

Patients reported significantly greater optimism about the future during bevacizumab treatment. They also reported less fear related to their care. Many described feeling anxious, depressed, or even traumatized by the cycle of repeated procedures. Some expressed fear of anesthesia complications or uncertainty about when the next surgery would be needed.

In contrast, many patients said bevacizumab reduced their stress and anxiety, increased their confidence, and gave them greater ability to engage in daily activities. The psychological burden of RRP is real, and this study shows that treatment choice can have a meaningful impact on mental well-being.

What Patients Prefer

When asked directly, the results were overwhelming. 83% of patients said they preferred bevacizumab over surgery. 83% believed bevacizumab offered a better quality of life. And 79% said they wanted to continue receiving bevacizumab treatment.

Among those who had stopped bevacizumab, the most common reasons were cost and access barriers, not dissatisfaction with the treatment itself. Two patients in the study noted that they had to access bevacizumab through clinical trials or grant-supported programs because their insurance did not cover it.

Why This Matters

This is the first study to directly compare patient-reported outcomes between systemic bevacizumab and surgical treatment within the same group of RRP patients. That makes it especially valuable. These are not two separate populations being compared. These are individuals reflecting on their own lived experiences with both approaches.

The findings support what emerging clinical guidelines have been suggesting: that bevacizumab should be considered as an earlier treatment option for eligible patients, and in some cases, even as a first-line therapy.

As the authors note, ensuring equitable access to treatments that meaningfully improve quality of life will be critical as RRP care continues to evolve.

What You Can Do

If you are living with RRP and have not yet discussed systemic bevacizumab with your care team, this study may be a helpful starting point for that conversation. You can access the full paper through Laryngoscope Investigative Otolaryngology.

For those who have experience with bevacizumab, your voice matters. Studies like this one are built on patient perspectives, and sharing your story helps shape the future of RRP care.

Read the full study: Gao S, et al. "Patient Perspectives on Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis." Laryngoscope Investigative Otolaryngology, 2026. doi: 10.1002/lio2.70500